|
|
Vaccine Detail
|
BCG for melanoma |
| Vaccine Information |
- Vaccine Name: BCG for melanoma
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Live, attenuated vaccine
- Status: Clinical trial
- Preparation: Forty-one patients were treated with BCG immunotherapy following block dissection of lymph nodes involved with malignant melanoma (Byrne et al., 1983).
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
|
Human Response
- Vaccine Immune Response Type: VO_0003057
- Immune Response: disease-free survival and overall survival of BCG-treated patients were not different from that of the control group, who received no immunotherapy (Byrne et al., 1983).
|
| References |
Byrne et al., 1983: Byrne MJ, Van Hazel G, Reynolds PM, Lemish WM, Holman CD. Adjuvant immunotherapy with BCG in stage II malignant melanoma. Journal of surgical oncology. 1983; 23(2); 114-116. [PubMed: 6343725].
|
|
